Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

• Published in: Journal of thrombosis and haemostasis 2021-12, Vol.19 (12), p.3008-3017
• Main Authors: Bosch, Floris T. M., Mulder, Frits I., Huisman, Menno V., Zwicker, Jeffrey I., Di Nisio, Marcello, Carrier, Marc, Segers, Annelise, Verhamme, Peter, Middeldorp, Saskia, Weitz, Jeffrey I., Grosso, Michael A., Duggal, Anil, Büller, Harry R., Wang, Tzu‐Fei, Garcia, David, Kamphuisen, Pieter Willem, Raskob, Gary E., Es, Nick
• Format: Article
• Language: English
• Subjects: Anticoagulants; Anticoagulants - adverse effects; Bleeding; Cancer; Case-Control Studies; Chemotherapy; factor Xa Inhibitors; Factor Xa Inhibitors - adverse effects; Gastrointestinal cancer; Gastrointestinal Hemorrhage - chemically induced; Gastrointestinal Hemorrhage - diagnosis; Gastrointestinal Hemorrhage - epidemiology; gastrointestinal neoplasms; Gastrointestinal Neoplasms - complications; Gastrointestinal Neoplasms - drug therapy; Hemoglobin; hemorrhage; Humans; Metastases; Original; Patients; Pyridines; Retrospective Studies; Risk Factors; Thiazoles; THROMBOSIS; Tumors; Venous Thromboembolism; venous thrombosis
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.15516

Background In the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identification of risk factors for gastrointestinal bleeding may help to guide the use of DOACs in these patients. Objectives To evaluate risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. Patients/Methods In this nested case‐control study in patients with gastrointestinal cancer randomized to edoxaban in the Hokusai VTE Cancer study, cases (patients with clinically relevant gastrointestinal bleeding during treatment) were randomly matched to three controls (patients who had no gastrointestinal bleeding). Data for the 4‐week period prior to bleeding were retrospectively collected. Odds ratios (ORs) were calculated in a crude conditional logistic regression model and a multivariable model adjusted for age, sex, and cancer type. Results Twenty‐four cases and 64 matched controls were included. In the multivariable analysis, advanced cancer, defined as regionally advanced or metastatic cancer (OR 3.6, 95% CI 1.01–12.6) and low hemoglobin levels (OR 4.8, 95% CI 1.5–16.0) were significantly associated with bleeding. There was no significant difference in patients with resected tumors (OR 0.4, 95% CI 0.1–1.4), or in patients on chemotherapy (OR 1.3, 95% CI 0.5–3.5). Conclusion Advanced cancer and low hemoglobin levels were associated with an increased risk of gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. We were unable to identify other risk factors, mainly due to limited statistical power.